Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Human Pathology|January 1, 1993
Systemic mastocytosis following mediastinal germ cell tumor: an association confirmedP Chariot, I Monnet, P Gaulard, et al.
The American Journal of Medicine|March 1, 1991
Systemic mast cell disease associated with primary mediastinal germ cell tumorP Chariot, I Monnet, F LeLong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1992
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT)I Monnet, P Chariot, E Quoix, et al.
The European Respiratory Journal|January 1, 1991
Histiocytic medullary reticulosis occurring with small cell lung carcinomaH de Cremoux, I Monnet, J Fleury, et al.
Chest|September 1, 1993
Miliary opacities diagnosed as lung metastases of a thyroid carcinoma after 13 years of stabilityP Chariot, A Feliz, I Monnet
Annals of Neurology|October 1, 1993
Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathyP Chariot, I Monnet, R Gherardi
Acta Neuropathologica|July 27, 2000
Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA- and nuclear DNA-encoded subunitsM Yerroum, C Pham-Dang, F J Authier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancerI Monnet, P Soulié, H de Cremoux, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)M Riggi, P Ruffie, S Voisin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra ThoraciquesI Monnet, S Brienza, F Hugret, et al.
Pageof 13